RO 7082859

Drug Profile

RO 7082859

Alternative Names: RO 7082859

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Roche
  • Class Antibodies; Antineoplastics
  • Mechanism of Action CD20 antigen inhibitors; CD3 antigen inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 07 Feb 2017 Phase-I clinical trials in Non-Hodgkin's lymphoma (Refractory metastatic disease) in Australia, Denmark and Spain (IV) (NCT03075696)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top